> Detailanzeige

Gregson, Stephen J.; Pugh, Kathryn; Patel, Neki; Afif-Rider, Shameen; Vijayakrishnan, Balakumar; Santos, Kathleen; Riedl, Jitka; Hutchinson, Ian; Kang, Gyoung-Dong; Chooi, K. Phin; Beard, Rhiannon; Adams, Lauren; Barry, Conor S.; Ball, Kathryn; Masterson, Luke A.; McFarlane, Mary; Hartley, John A.; Howard, Philip W.

Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody–Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody–Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer
  • Beteiligte: Gregson, Stephen J.; Pugh, Kathryn; Patel, Neki; Afif-Rider, Shameen; Vijayakrishnan, Balakumar; Santos, Kathleen; Riedl, Jitka; Hutchinson, Ian; Kang, Gyoung-Dong; Chooi, K. Phin; Beard, Rhiannon; Adams, Lauren; Barry, Conor S.; Ball, Kathryn; Masterson, Luke A.; McFarlane, Mary; Hartley, John A.; Howard, Philip W.
  • Erschienen: American Association for Cancer Research (AACR), 2022
  • Erschienen in: Molecular Cancer Therapeutics, 21 (2022) 9, Seite 1439-1448
  • Sprache: Englisch
  • DOI: 10.1158/1535-7163.mct-22-0145
  • ISSN: 1535-7163; 1538-8514
  • Schlagwörter: Cancer Research ; Oncology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: Abstract Antibody–drug conjugate (ADC) research has typically focused on the release of highly potent cytotoxic agents to achieve antitumor efficacy. However, recently approved ADCs trastuzumab deruxtecan and sacituzumab govitecan release lower-potency topoisomerase inhibitors. This has prompted interest in ADCs that release lower-potency cytotoxic drugs to potentially enhance therapeutic index and reduce unwanted toxicity. Pyrrolobenzodiazepine (PBD) dimer ADCs have been widely investigated in human clinical trials, which have focused on high-potency PBDs. In this study, we evaluated five ADCs that release the low-potency PBD dimer SG3650. The relatively low clogD for this agent facilitated higher drug-to-antibody ratio (DAR) conjugation without the need for antibody engineering or functionalization of the drug. The rank order of potency for DAR 2 site-specific ADCs (conjugated at the C239i position) matched the order for the corresponding free drugs in vitro. Despite free drug SG3650 being inactive in vivo, the DAR 2 ADCs derived from the corresponding drug-linker SG3584 showed antitumor efficacy in solid (anti-HER2) and hematologic (anti-CD22) xenograft models. Antitumor activity could be enhanced by conjugating SG3584 to trastuzumab at higher DARs of 4 and 8 and by adjusting dosing and schedule. Higher-DAR conjugates were stable and displayed good rat pharmacokinetic profiles as measured by ELISA and LC/MS-MS. A single intravenous dose of isotype control SG3584 DAR 2 ADC resulted in no mortality in rats or monkeys at doses of up to 25 and 30 mg/kg, respectively. These findings suggest that further investigations of low-potency PBD dimers in ADCs that target hematologic and solid tumors are warranted.
  • Zugangsstatus: Freier Zugang